Tel: +44 (0)20 7691 0984 | contact@transpharmation.co.uk
 

EEG

At Transpharmation we have established a highly translatable in-vivo electrophysiology telemetry platform in rodents, providing support for the CNS pharmacodynamic activity of novel test compounds.

Sleep/Wake

sleepTranspharmation has a world-class pedigree in Sleep/EEG research. Our expertise in this field stems from research conducted by our management team whilst at GSK, on the central arousal effect of the hypothalamic neuropeptide orexin-A, pivotal in guiding the discovery and development of novel orexin receptor antagonists for a range of sleep disorders. At Transpharmation, we benchmark compounds against clinically relevant standards such as zolpidem and modafinil to evaluate CNS stimulant or sedative/hypnotic properties on sleep/wake cycles in rodents; supporting our clients in the development of novel molecules for a range of therapeutic indications, including sleep disorders.


Quantitative EEG (QEEG)

EEG icon1The use of QEEG is fundamental in drug discovery given the high predictive and back-translational validity it offers researchers. QEEG methods allow the identification of CNS pharmacodynamic effects of novel test compounds on spectral power frequency bands, recorded from both surface and depth electrodes, providing a highly relevant translational biomarker that can be applied to the clinical setting. For example, QEEG can be used to detect increased gamma oscillations in putative pro-cognitive compounds, benchmarked against gold standards such as donepezil and memantine. Importantly QEEG studies can help to guide strategic decision-making around dose-prediction, PK/PD (concentration-effect) relationships as well as site and mechanism of action for a novel CNS penetrant test compound.


Mismatch-negativity (MMN)

MMNAt Transpharmation, we've applied our expertise in EEG to develop rodent mismatch negativity (MMN) - regarded as one of the most highly-translatable biomarkers for schizophrenia. MMN is a human scalp recorded event related potential (ERP) component elicited by a sound which deviates from a repeating pattern of recent sounds. MMN is generated by a temporo-frontal network including the auditory cortex and is known to be diminished in schizophrenic patients. This disruption can be mimicked by NMDA antagonists (e.g. ketamine) treatment in healthy volunteers. Via collaborations with Cadent and Lundbeck, we have thoroughly validated our MMN protocols with NMDA antagonists such as MK-801, PCP and ketamine in rodents using in-vivo EEG, demonstrating the utility of MMN as a potential translational marker for novel treatments for schizophrenia.

 

Examples of the models we offer include:

Examples of end points:

  • REM, non-REM, latency to sleep onset, paradoxical sleep quantification etc.
  • Power spectral band analysis – delta, theta, gamma, beta, alpha frequencies
  • PK analysis

pain1This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

uk flag +44 (0)20 7691 0984

ireland flag +353 (0)1896 42 60

mail contact@transpharmation.co.uk


Copyright

Copyright © 2019 Transpharmation Ltd. All Rights Reserved.

Copyright © 2019 Transpharmation Ltd. All Rights Reserved. Website created by Identity Ipswich Web Design